

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Sisram Medical Ltd**  
**復銳醫療科技有限公司\***  
*(Incorporated in Israel with limited liability)*  
**(Stock Code: 1696)**

**VOLUNTARY ANNOUNCEMENT**

This announcement is made by Sisram Medical Ltd (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that the drug registration application of RT002 (DaxibotulinumtoxinA, the “**New Drug**”), a product sublicensed by Shanghai Fosun Pharmaceutical Industrial Development Company Limited\* (上海復星醫藥產業發展有限公司) (“**Fosun Pharmaceutical Industrial**”) which is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients, was accepted by the National Medical Products Administration. As at the date of this announcement, there was no Daxibotulinumtoxin A Botulinum Toxin product launched for sale in China.

The Company was granted by Fosun Pharmaceutical Industrial in December 2022 the sublicense rights to use, import, sales and other commercial activities (excluding manufacturing) of the New Drug in the Region (i.e. Mainland China, Hong Kong and Macau Special Administrative Regions, hereinafter the same). The head licensor, Revance Therapeutics, Inc. which is based in the U.S., is still the owner of the New Drug in the Region. The New Drug is a biological product which is intended for aesthetic indications. According to the sublicense agreement, the RT002 aesthetic indications apply to the treatment, minimization and/or eradication of, or the appearance of any lines and wrinkles on the body, including but not limited to facial glabellar lines and crow’s feet.

Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.

On behalf of the Board  
**Sisram Medical Ltd**  
**復銳醫療科技有限公司\***  
**Yi LIU**  
*Chairman*

Hong Kong, April 11, 2023

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU and Mr. Lior Moshe DAYAN as Executive Directors; Mr. Yifang WU and Ms. Rongli FENG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.*

\* for identification purpose only